Vol 8, No 2 (2022)
Review paper
Published online: 2022-03-24

open access

Page views 2557
Article views/downloads 116
Get Citation

Connect on Social Media

Connect on Social Media

Sweet’s syndrome — etiopathogenesis, clinical presentation, diagnosis, treatment

Anna Czaplicka1, Jakub Biliński1, Klaudia Dopytalska1, Irena Walecka1
Forum Dermatologicum 2022;8(2):63-68.

Abstract

Sweet’s syndrome is a rare inflammatory disorder belonging to the group of neutrophilic dermatoses. It is characterized by a sudden onset of skin lesions such as papules, nodules, plaques, accompanied by fever and leukocytosis. The syndrome is typically classified into the following subtypes: classical, malignancy-associated and drug-induced. The etiopathogenesis of Sweet’s syndrome remains unclear. The syndrome is sometimes preceded by infection of the respiratory system, digestive system, vaccination or coexists with neoplastic disease, inflammatory disease or pregnancy. A characteristic feature of Sweet’s syndrome is a good response to systemic treatment with glucocorticosteroids and a rapid resolution of the lesions. On average, one third of patients have recurrent lesions.

Article available in PDF format

View PDF (Polish) Download PDF file

References

  1. Sweet RD. An acute febrile neutrophilic dermatosis. Br J Dermatol. 1964; 76: 349–356.
  2. Villarreal-Villarreal CD, Ocampo-Candiani J, Villarreal-Martínez A. Sweet Syndrome: A Review and Update. Actas Dermosifiliogr. 2016; 107(5): 369–378.
  3. Nelson CA, Stephen S, Ashchyan HJ, et al. Neutrophilic dermatoses: Pathogenesis, Sweet syndrome, neutrophilic eccrine hidradenitis, and Behçet disease. J Am Acad Dermatol. 2018; 79(6): 987–1006.
  4. Heath MS, Ortega-Loayza AG. Insights Into the Pathogenesis of Sweet's Syndrome. Front Immunol. 2019; 10: 414.
  5. Marzano AV, Ortega-Loayza AG, Heath M, et al. Mechanisms of Inflammation in Neutrophil-Mediated Skin Diseases. Front Immunol. 2019; 10: 1059.
  6. Nelson CA, Noe MH, McMahon CM, et al. Sweet syndrome in patients with and without malignancy: A retrospective analysis of 83 patients from a tertiary academic referral center. J Am Acad Dermatol. 2018; 78(2): 303–309.e4.
  7. Kumar G, Bernstein JM, Waibel JS, et al. Sweet's syndrome associated with sargramostim (granulocyte-macrophage colony stimulating factor) treatment. Am J Hematol. 2004; 76(3): 283–285.
  8. Nelis S, Azerad MA, Drowart A, et al. [Sweet's syndrome induced by pegfilgrastim during a myelodysplastic syndrome AREB2: A case report]. Rev Med Interne. 2019; 40(4): 258–261.
  9. Pérez-Feal P, Pita da Veiga G, Moreiras-Arias N, et al. Sweet's syndrome triggered by ultraviolet light. Photodiagnosis Photodyn Ther. 2021; 34: 102258.
  10. Ramsey AL, Wallace WD, Abtin F, et al. Sweet's Syndrome: A First in Human Lung Transplantation. Chest. 2021; 160(2): e173–e176.
  11. Sechi A, Pierobon E, Pezzolo E, et al. Abrupt onset of Sweet syndrome, pityriasis rubra pilaris, pityriasis lichenoides et varioliformis acuta and erythema multiforme: unravelling a possible common trigger, the COVID-19 vaccine. Clin Exp Dermatol. 2022; 47(2): 437–440.
  12. Darrigade AS, Théophile H, Sanchez-Pena P, et al. Sweet syndrome induced by SARS-CoV-2 Pfizer-BioNTech mRNA vaccine. Allergy. 2021; 76(10): 3194–3196.
  13. von den Driesch P, von den Driesch P, Dannecker GE, et al. Sweet's syndrome (acute febrile neutrophilic dermatosis). J Am Acad Dermatol. 1994; 31: 535–556.
  14. Walker DC, Cohen PR. Trimethoprim-sulfamethoxazole-associated acute febrile neutrophilic dermatosis: case report and review of drug-induced Sweet's syndrome. J Am Acad Dermatol. 1996; 34(5 Pt 2): 918–923.
  15. Shahid Z, Kalayanamitra R, Patel R, et al. Refractory Sweet Syndrome Treated with Anakinra. Cureus. 2019; 11(4): e4536.